Xbrane Biopharma

Xbrane Biopharma Gross Margin

The Gross Margin of Xbrane Biopharma (XBRANE.ST) as of Oct 18, 2026 is 52.23 %. In the previous year, Gross Margin was 90.83 % — a change of -42.50% (lower).

Gross Margin

52.23 %

YoY

-42.50%

Last updated:

Gross Margin of Xbrane Biopharma is 2025 52.23 % . Gross Margin of Xbrane Biopharma was 2024 90.83 % . It decreases by -42.50% lower compared to the previous year.

Xbrane Biopharma's gross margin stands at 52.2%, up from -5.9% several years earlier.

The Xbrane Biopharma Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
85.92 SEK
Jan 1, 2019
-2,945.17 SEK
Jan 1, 2020
35.93 SEK
Jan 1, 2021
-5.93 SEK
Jan 1, 2022
71.23 SEK
Jan 1, 2023
14.82 SEK
Jan 1, 2024
90.83 SEK
Jan 1, 2025
52.23 SEK
The Xbrane Biopharma Gross Margin history
YEARGross MarginYoY
52.23 %-42.50%
90.83 %+512.73%
14.82 %-79.19%
71.23 %-1,301.04%
-5.93 %-116.51%
35.93 %-101.22%
-2,945.17 %-3,527.91%
85.92 %+261.11%
23.79 %-114.34%
-165.89 %-506.61%
40.80 %-59.20%
100.00 %+20,737.01%
0.48 %-287.13%
-0.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Xbrane Biopharma Stock analysis

What does Xbrane Biopharma do? Xbrane Biopharma AB, based in Solna, Sweden, operates in the Health Care sector as a biotechnology company specializing in the development and manufacturing of biosimilars. The company employs 92 full-time staff and focuses on injectable slow-release drugs and high-yield protein expression technology. Key products include Sperotide, a biosimilar to Decapeptyl, Trelstar, and Pamorelin, and Xlucane, a biosimilar to Lucentis, both developed for injectable use. Xbrane Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Xbrane Biopharma stock

Gross Margin of Xbrane Biopharma is 52.23 % in 2025.

Gross Margin of Xbrane Biopharma changed from 90.83 % to 52.23 %, representing a -42.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Xbrane Biopharma since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Xbrane Biopharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Xbrane Biopharma

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Xbrane Biopharma